Bradykinin (trifluoroacetate salt)
目录号 : GC49880
An endogenous vasodilator
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Bradykinin is a 9-
1.Barrow, S.E., Dollery, C.T., Heavey, D.J., et al.Effect of vasoactive peptides on prostacyclin synthesis in manBr. J. Pharmacol.87(1)243-247(1986) 2.Campbell, W.B., Falck, J.R., and Gauthier, K.Role of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factor in bovine coronary ateriesMed. Sci. Monit.7(4)578-584(2001) 3.Ju, H., Venema, V.J., Marrero, M.B., et al.Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthaseJ. Biol. Chem.273(37)24025-24029(1998) 4.Dray, A., and Read, S.J.Future targets to control osteoarthritis painArthritis Res. Ther.9(3)212-225(2007) 5.Figini, M., Emanueli, C., Grady, E.F., et al.Substance P and bradykinin stimulate plasma extravasation in the mouse gastrointestinal tract and pancreasAm. J. Physiol.272G785-G793(1997) 6.Heavey, D.J., Barrow, S.E., Hickling, N.E., et al.Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in manNature318(6042)186-188(1985) 7.Cushman, D.W., and Ondetti, M.A.Design of angiotensin converting enzyme inhibitorsNat. Med.5(10)1110-1113(1999)
| Cas No. | SDF | Download SDF | |
| Canonical SMILES | O=C([C@H](CCC1)N1C([C@@H](N)CCCNC(N)=N)=O)N(CCC2)[C@@H]2C(NCC(N[C@H](C(N[C@@H](CO)C(N(CCC3)[C@@H]3C(N[C@H](C(N[C@H](C(O)=O)CCCNC(N)=N)=O)CC4=CC=CC=C4)=O)=O)=O)CC5=CC=CC=C5)=O)=O.OC(C(F)(F)F)=O | ||
| 分子式 | C50H73N15O11 • XCF3COOH | 分子量 | 1060.2 |
| 溶解度 | DMF: 20 mg/mL,DMSO: 10 mg/mL,Ethanol: 5 mg/mL,PBS (pH 7.2): 1 mg/mL | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9432 mL | 4.7161 mL | 9.4322 mL |
| 5 mM | 0.1886 mL | 0.9432 mL | 1.8864 mL |
| 10 mM | 0.0943 mL | 0.4716 mL | 0.9432 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Comparison of an organic polymeric column and a silica-based reversed-phase for the analysis of basic peptides by high-performance liquid chromatography
J Chromatogr A 2005 May 6;1073(1-2):137-45.PMID:15909515DOI:10.1016/j.chroma.2004.10.023.
The performance of a purely polymeric and a Type B silica-based C18 reversed-phase column was compared for the analysis of the basic peptide Bradykinin and some analogues in order to assess the contribution of silanol interactions to peak shape. Good peak shapes were obtained for small masses of these peptides (0.1 microg or less) using acidic mobile phases on both columns; however, both showed a similar and serious deterioration in peak shape with increasing sample mass. Loss of efficiency on both columns as sample mass increased was considerably more serious when using formic acid rather than trifluoroacetic acid (TFA) as a mobile phase additive. For example, the peak capacity for a 2.5 microg load of one Bradykinin on the polymeric column was reduced to only 0.38 times its value for 0.1 microg when using 0.02 M formic acid, compared with 0.77 times its value when using the same concentration of TFA. This result can be attributed to the ion pair effect of TFA and its higher ionic strength, which reduce mutual repulsion of charged peptides when held on the hydrophobic surface of the phase. Addition of salt (KCl) to the formic acid mobile phase caused dramatic increases in retention on the polymeric column, which can also be attributed to ion-pairing effects between halide ions and peptides. The increase in retention with salt addition also confirms that there are no ionic retention sites on the polymeric phase at low pH. The general similarity in behaviour between the polymeric and silica column suggests that silanol groups have little involvement in the retention and overload behaviour of these peptides when using highly inert Type B silica phases.